Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
25 participants
INTERVENTIONAL
2024-03-20
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
the Treatment of Postpartum Hemorrhage Due to Placenta Previa Complete Centralis
NCT02157441
Transverse B-Lynch in Management of Placenta Accreta
NCT02943421
Simplified Conservative Measures in Managing Morbidly Adherent Placenta in Beni-Suef University
NCT06465836
Balloon Tamponade Vs B-Lynch In Placenta Previa
NCT05133167
The Cervix as a Natural Tamponade in Postpartum Hemorrhage Caused by Placenta Previa and Placenta Previa Accreta
NCT02590484
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The needle is retrieved through the cavity of the uterus and pulled inferiorly with the suture material lying on the posterior wall of the uterine cavity. The needle then perforates the posterior wall of the uterus 1-3 cms below the inferior margin of the Caesarean incision and exists behind the vascular bundle of the same side of the uterus retrieved and runs on the surface of the lower segment below the incision margin parallel to it and taking a 1 cm bite of tissue for stabilization running to the other side.
After encircling the para-uterine vasculature, the needle then perforates the posterior side of the uterus behind the vascular bundle entering the uterine cavity 1-3 cm below the inferior margin of the Caesarean incision. The suture can lie freely on the posterior wall of the uterine cavity and exists 3 cms above the upper margin of the Caesarean incision. It exits posteriorly and behind the vascular bundle to meet the suture from the other side.
It is essential that the ureters are identified by palpation or visual observation after the bladder is displaced inferiorly and held by traction. Any observed bleeding should be dealt with in the usual way. At the end of the suture application and before tying the knots, the lower segment is compressed again transversely whilst the suture is held taut to ensure that bleeding has ceased by swabbing the vagina again.
A wide pore drain will be inserted in the Douglas pouch, and the abdominal wall will be repaired.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
B-Lynch Transverse Compression Suture
Transverse B-Lynch suture will be performed to these patients as a method of controlling postpartum heamorrhage in placenta previa patients
B-Lynch Transverse Compression Suture
closure of uterine and utero ovarian arteries bilaterally with one suture
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
B-Lynch Transverse Compression Suture
closure of uterine and utero ovarian arteries bilaterally with one suture
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Elective CS for placenta preiva (diagnosed by transvaginal ultrasound).
3. Muliparity (para 2 or more).
Exclusion Criteria
• Ultrasonographic features of morbidly adherent placentas:
* Loss of Retro-placental sonolucent zone.
* Vascular lacunae.
* Myometrial thinning.
* Interruption of the bladder border.
2. More than 3 previous C.S.
3. Severely haemodynamic instablility needing immediate hysterectomy.
4. Patients with the cardiac, hepatic, renal or thromboembolic disease
5. Patients with coagulopathy:
* Receiving anticoagulant therapy.
* With thrombocytopenia or thrombasthenia.
* Known coagulation factor defect.
6. Distorted uterus as unicornuate, bicornuate, fibroid uterus and adenomyosis uteri.
18 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alexandria University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Zeerban
Doctor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain Shams University
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Asmaa F Kassem, MD
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FMASU MD 292/2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.